FDA’s Summit rejection puts PD-1xVEGF class on notice to establish overall survival
The FDA rejected Summit Therapeutics’ ivonescimab over the weekend, sending a strong message to rival drugmakers Bristol Myers Squibb, BioNTech, Pfizer, Merck and AbbVie.
comments(0)
5-min edit window · permanent after that